Fulgent Genetics (FLGT) Net Income towards Common Stockholders (2015 - 2026)

Fulgent Genetics has disclosed Net Income towards Common Stockholders across 12 years of filings, most recently posting -$29.5 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 55.77% year-over-year to -$29.5 million; the TTM figure through Jun 2026 stood at -$84.4 million (down 65.38% YoY), while the FY2025 annual figure was -$60.5 million, down 41.69% from the prior year.
• Net Income towards Common Stockholders came in at -$29.5 million for Q2 2026 at Fulgent Genetics, down from -$24.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $153.6 million in Q1 2022 to a low of -$128.1 million in Q4 2023.
• Average Net Income towards Common Stockholders over 5 years is -$10.2 million, with a median of -$13.3 million recorded in 2023.
• Year-over-year, Net Income towards Common Stockholders tumbled 1075.95% in 2023 and surged 95.41% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at -$24.1 million in 2022, then sank by 432.27% to -$128.1 million in 2023, then surged by 95.41% to -$5.9 million in 2024, then tumbled by 297.72% to -$23.4 million in 2025, then dropped by 26.1% to -$29.5 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$29.5 million in Q2 2026, -$24.8 million in Q1 2026, and -$23.4 million in Q4 2025.